» Authors » Alessandro Broccoli

Alessandro Broccoli

Explore the profile of Alessandro Broccoli including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 127
Citations 1111
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Broccoli A, Zinzani P
Recenti Prog Med . 2025 Mar; 116(3):e37-e39. PMID: 40084457
No abstract available.
2.
Pellegrini C, Casadei B, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, et al.
Ann Hematol . 2025 Mar; PMID: 40025210
Immune checkpoint inhibitors (CPIs) emerged as an effective and safe therapeutic option for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, many patients lose their response to CPIs. To...
3.
Casadei B, Argnani L, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, et al.
Blood Adv . 2025 Feb; PMID: 39993241
No abstract available.
4.
Broccoli A, Zinzani P
Recenti Prog Med . 2025 Feb; 116(2):e21-e23. PMID: 39931888
No abstract available.
5.
Broccoli A, Del Re M, Danesi R, Zinzani P
J Cell Mol Med . 2025 Jan; 29(3):e70170. PMID: 39887627
Bruton tyrosine kinase (BTK), the primary target of BTK inhibitors, is a key enzyme in the proliferation and survival pathway of neoplastic B-cells. BTK inhibitors are approved in many hematologic...
6.
Broccoli A, Zinzani P
Recenti Prog Med . 2025 Jan; 116(1):1e-3e. PMID: 39840878
No abstract available.
7.
8.
Mazzoni C, Argnani L, Casadei B, Broccoli A, Gabrielli G, Fabbri N, et al.
Eur J Haematol . 2024 Sep; 114(1):70-78. PMID: 39295142
First-line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except for eradication therapy for Helicobacter pylori in early gastric MZL. Various regimens, for example, locoregional...
9.
Broccoli A, Margiotta-Casaluci G, Pagani C, Steffanoni S, Viviani S, Zinzani P, et al.
Leuk Lymphoma . 2024 Sep; 65(14):2207-2210. PMID: 39225366
No abstract available.
10.
Casadei B, Conti G, Barone M, Turroni S, Guadagnuolo S, Broccoli A, et al.
Hematol Oncol . 2024 Aug; 42(5):e3301. PMID: 39104142
Biomarkers for immune checkpoint inhibitors (ICIs) response and resistance include PD-L1 expression and other environmental factors, among which the gut microbiome (GM) is gaining increasing interest especially in lymphomas. To...